drugset / Trial / NCT01175148
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Atorvastatin for prevention of acute GVHD
Timeline
- Start
- 2010-07
- Primary completion
- 2014-12
- Completion
- 2014-12
Publications
- Background Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood. 2008 Apr 1;111(7):3901-2. doi: 10.1182/blood-2008-01-132050. No abstract available.
- Background Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007 Dec 15;110(13):4588-98. doi: 10.1182/blood-2007-08-106005. Epub 2007 Sep 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | Oral |